Close
What would you like to look for?
Site search
12 December 2019

ARTIDIS AG ("ARTIDIS"), a privately held healthtech company, announced the successful closure of a CHF 8.8M seed financing in two rounds, securing early clinical validation and the next development phase towards market entry in 2021. The funding will be used to advance the company’s healthtech platform into a large multicentre clinical study aiming to further validate the value of ARTIDIS in diagnosing breast and lung cancer, as well as for personalizing and optimizing cancer treatment.

VISCHER AG acted as counsel to ARTIDIS. The team was led by Matthias Staehelin (Partner, Corporate) and supported by Fiona Gao and Luzius Zumstein (Associates, Corporate).

Press release

Authors